Le Lézard
Classified in: Health
Subjects: PDT, FDA

Douglas Medical Products Inc. Receives FDA 510(k) Clearance for the TUBETECH® IV Administration Set


MUNDELEIN, Ill., Sept. 12, 2017 /PRNewswire/ -- Douglas Medical Products, Inc., a growing medical device company focused on contract manufacturing of IV Administration/Extension Sets and Enteral (ENFit) Sets, announced today that it has received 510(k) clearance for TUBETECH® IV Administration Sets from the U.S. Food and Drug Administration (FDA).  TUBETECH® IV Administration Sets are cleared for use in peristaltic IV infusion pumps. This FDA clearance allows Douglas Medical Products to begin immediate commercialization of TUBETECH® IV Administration Sets for use in peristaltic IV infusion pumps.

"We are pleased to have received 510(k) clearance for the TUBETECH® IV Administration Set," stated Doug Johnson, Douglas Medical Products CEO.  "TUBETECH® technology brings new innovative solutions to current issues of IV tubing performance in peristaltic IV infusion pumps. We expect many of our customers will benefit by having TUBETECH® IV Administration Sets available for use in hospitals, alternative site settings and long-term care facilities.  The entrepreneurial mindset within Douglas Medical Products continues to bring innovative and disruptive new products to solve problems for our customers and the market place."

About Douglas Medical Products
Douglas Medical Products (DMP), is a full-service, high quality, contract manufacturer producing a full line of standard and custom IV Administration/Extension Sets, Enteral(ENFit) Sets and Surgical Kit products.  DMP has a broad range of 510(k)'s and continues to add additional 510(k)'s for new products and to support our customers' future strategic objectives. The Company's mission is to service the market with next generation products, innovative technology and cost-effective production. DMP capabilities include engineering, design, CAD, 100,000 clean room, injection molding, high precision extrusion, all types of assembly operations, and regulatory support. DMP can support development of new products from initial concept to full production. This enables our customers to offer private label products to expand their market presence and penetrate new markets.  DMP customer base includes companies from start-ups to large corporations. The leadership team has over 60 years of experience in medical devices and partners with their customers to bring products to market on time and cost effectively.

Douglas Medical Products looks forward to making TUBETECH® unique solutions available to new customers for use in peristaltic IV infusion pumps. Contact us on how to order TUBETECH® Sets.

Additional Information:

Douglas Medical Products, Inc., visit www.douglasmedicalproducts.com   

Contact:
Doug Johnson                                     
Douglas Medical Products, Inc. 
[email protected]                           
+1 847 909 4298

 

SOURCE Douglas Medical Products, Inc.


These press releases may also interest you

at 08:25
The "OPDIVO Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about OPDIVO for ovarian cancer in the six major markets. A detailed picture of...

at 08:25
Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that President and Chief Medical Officer Dr. Fred Grossman, D.O., FAPA...

at 08:20
4Sight Labs, pioneers in biometric monitoring solutions for custody environments, today announced the launch of OverWatchtm, the first-of-its-kind, comprehensive biometric monitoring system designed to address the wellness and safety of individuals...

at 08:20
Anixa Biosciences, Inc. ("Anixa" or the "Company") , a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Sanjay Juneja, MD to its Cancer Business Advisory Board....

at 08:15
Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 second quarter ended...

at 08:15
EditCo Bio, Inc., a pioneer at the forefront of genome engineering innovation, today announced the launch of its Knockout CD4+ T-cell Pools. This latest addition to EditCo Bio's product lineup marks a significant leap forward in CRISPR-mediated gene...



News published on and distributed by: